首页|期刊导航|中国中西医结合急救杂志|ICU患者谵妄药物防治研究进展

ICU患者谵妄药物防治研究进展OA

Research advances in pharmacological prevention and treatment of delirium in intensive care unit patients

中文摘要英文摘要

谵妄是危重症患者常见的脑功能障碍.重症监护病房(ICU)患者谵妄发病率高达 50%~80%.谵妄的发生会导致患者机械通气时间、ICU 住院时间、总住院时间延长,病死率和医疗费用增加等,同时影响患者长期认知功能.由于谵妄发生的病理生理学机制尚不明确,目前 ICU 患者谵妄的药物防治仍处于不断探索中.常见的谵妄预防性药物有抗精神病药、右美托咪定、褪黑素、他汀类药物、氯胺酮等,但目前指南并不推荐任何一种药物预先使用来防止谵妄发生.而治疗谵妄的药物,如抗精神病药、右美托咪定、可乐定及丙戊酸钠等,存在一定的不良反应且证据不充分.目前谵妄防治缺乏明确有效的药物,仍需继续深入研究.

Delirium is a common acute cerebral dysfunction syndrome in critically ill patients,The incidence of delirium in intensive care unit(ICU)patients is as high as 50%to 80%.Delirium can lead to prolonged mechanical ventilation,ICU and hospital stays,increased mortality,and medical costs,as well as affecting long-term cognitive function.Because the pathophysiological mechanism of delirium is unclear,pharmacological prevention and treatment of delirium in ICU patients remains to be further explored.Common prophylactic medications for delirium include antipsychotics,dexmedetomidine,melatonin,statins,ketamine,and other agents,but current guidelines do not recommend any drug for routine prophylactic use against delirium.However,drugs used to treat delirium,such as antipsychotics,dexmedetomidine,clonidine,and valproic acid,have side effects and lack sufficient evidence.Currently,research on the prevention and treatment of delirium lacks clearly effective pharmacological agents,and further in-depth investigation remains necessary.

何德华;王迪芬;刘旭

贵州医科大学附属医院重症医学科,贵州 贵阳 550004贵州医科大学附属医院重症医学科,贵州 贵阳 550004贵州医科大学附属医院重症医学科,贵州 贵阳 550004

重症监护病房谵妄药物预防治疗

Intensive care unitDeliriumPharmacological interventionsPreventionTreatment

《中国中西医结合急救杂志》 2026 (2)

236-241,6

国家重点研发计划项目(2018YFC2001904)中华国际医学交流基金会中青年医学研究专项基金(Z-2018-35-2101)贵州省科技成果转化及产业化项目(临床专项)(黔科合成果LC[2025]一般 133) National Key Research and Development Plan of China(2018YFC2001904)Special Fund for Young and Middle-aged Medical Research of China International Medical Foundation(Z-2018-35-2101)Guizhou Provincial Science and Technology Transformation and Industrialization Program(Clinical Special Project)(Qian Ke He LC[2025]General 133)

10.3969/j.issn.1008-9691.2026.02.019

评论